• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    McKesson (MCK) Earnings Beat Raises The Question Of Whether The Stock Is Fully Valued

    Simply Wall St·11/04/2026 05:40:21
    Listen to the news

    McKesson (MCK) is back in focus after strong third quarter results, with adjusted earnings per share up 20%, GLP-1 distribution reaching $15b, higher full year guidance, and a 15% dividend increase.

    That earnings beat is landing on top of already strong momentum. McKesson’s share price has gained 10.79% over the past month and 21.40% year to date, while the 5-year total shareholder return of 367.39% points to a long-running, market-beating compounding story.

    Spot 35 high quality undervalued stocks that, like McKesson after its latest earnings and dividend news, pair resilient fundamentals with pricing that may not fully reflect their underlying strength.

    Bulls point to McKesson’s rising earnings, dividend growth and GLP-1 exposure, while bears focus on how much good news is already priced in. Which story do the current valuation numbers really support?

    Most Popular Narrative: 2.6% Undervalued

    McKesson’s most followed narrative pegs fair value at $1,026.07, slightly above the last close of $999.62, which frames the current pricing debate around specialty growth and GLP 1 exposure.

    Increasing adoption of specialty and oncology pharmaceuticals, together with the build out of multispecialty platforms such as US Oncology Network and PRISM, is shifting McKesson’s mix toward higher margin services that can support operating margin and earnings growth.

    Integration of Precision Medicine Group into McKesson’s oncology ecosystem, including clinical research and commercialization capabilities, is expected to create a fuller service offering to biopharma customers that can support future revenue growth and margin expansion in the Oncology & Multispecialty segment.

    See why 63 investors see McKesson as 3% undervalued.

    According to this widely followed view, a 7.24% discount rate and forecasts for earnings of $6.4b by 2029 combine with a future P/E assumption of 19.6x to arrive at that $1,026.07 fair value. The modest 2.6% gap to the latest share price suggests the market is already crediting much of McKesson’s oncology shift, RxTS scale and capital return plans, while still leaving a small cushion if those profit and buyback assumptions play out as expected.

    Result: Fair Value of $1,026.07 (UNDERVALUED)

    Still, the narrative can crack if drug pricing pressure squeezes McKesson’s thin net margin near 1.27% or if cyber incident fallout drives higher costs and customer losses.

    Find out about the key risks to this McKesson narrative.

    Next Steps

    Mixed signals have emerged so far regarding McKesson’s risk and reward profile. Act while the data is fresh and weigh both sides by reviewing the 3 key rewards and 1 important warning sign

    Looking for more ideas beyond McKesson?

    Do not stop with McKesson. Use fresh data and clear filters to uncover other opportunities that fit your style before the crowd pays attention.

    • Target potential value setups by scanning a curated 35 high quality undervalued stocks that pair robust business quality with prices that may not fully reflect their fundamentals.
    • Strengthen your income focus by zeroing in on a hand picked 4 dividend fortresses designed for investors who want yield with substance behind it.
    • Lower portfolio stress by filtering for a 30 resilient stocks with low risk scores that highlights resilient businesses with steadier profiles when conditions change.